Joaquin Duato, J&J CEO (David Zorrakino/Europa Press via Getty Images)
J&J downsizes infectious disease and vaccine pipeline, cutting hepatitis B programs
Johnson & Johnson has culled seven programs from its infectious disease pipeline since the first quarter of the year, most of which are hepatitis B …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
